Hims & Hers Health faces slowing revenue/subscriber growth, premium valuation and regulatory risk from copycat obesity drugs. Learn more about HIMS stock here.

The Fed's three rate cuts and Lululemon's ongoing bottoming in US sales have already triggered the stock's outsized rally by +74.9% from the August 2024 bottom. The positive sentiments are further ...

A study by Queen Mary University of London reveals that nature's 'self-repairing engine' that counters global warming and biodiversity loss may be slowing down. Analyzing global biodiversity data, ...